Researchers at the Technion have developed an innovative artificial intelligence (AI) model that accurately predicts whether early-stage breast cancer patients will benefit from chemotherapy. This breakthrough addresses a longstanding challenge faced by oncologists, balancing potential treatment benefits against severe side effects. The AI system analyzes digital tissue samples taken at diagnosis, assessing patterns related to cancer behavior, such as cell structure and immune response. Unlike traditional genomic tests, which are costly and time-consuming, this method provides a numerical score for recurrence risk and chemotherapy benefit within minutes. The model, validated by extensive clinical trials, enhances access to personalized cancer treatments, especially in developing nations where genomic testing is limited. The AI could streamline oncology care while reducing unnecessary chemotherapy. Following successful trials, the team plans to implement this technology in Israel and further test it in Brazil and India, with potential applications for various cancers. This innovation could transform oncology practices worldwide.
Source link
